CD4+CAR T-cell expansion is associated with response and therapy related toxicities in patients with B-cell lymphomas

Article Oncology

Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study

Michael Wang et al.

Summary: Brexucabtagene autoleucel (KTE-X19) autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has shown durable long-term responses with manageable safety in patients with relapsed/refractory mantle cell lymphoma (MCL) and may benefit those with high-risk characteristics.

JOURNAL OF CLINICAL ONCOLOGY (2023)

添加到收藏夹

Article Multidisciplinary Sciences

Decade-long leukaemia remissions with persistence of CD4(+) CAR T cells

J. Joseph Melenhorst et al.

Summary: CAR T cells redirected to target CD19 demonstrated long-lasting potential and clonal stability in two patients with chronic lymphocytic leukaemia. Highly activated CD4(+) cells emerged and dominated the CAR T cell population at later time points. These unexpected CAR T cell populations provide novel insights into anti-cancer response and long-term remission in leukaemia.

NATURE (2022)

添加到收藏夹

Article Oncology

Cytopenia after CAR-T Cell Therapy-A Brief Review of a Complex Problem

Naman Sharma et al.

Summary: CAR-T immunotherapy, a new treatment modality, modifies the patient's T cells to recognize and kill cancer cells. However, it comes with immune side effects such as cytokine release syndrome and prolonged cytopenia. This review summarizes clinical trials, mechanisms, and interventions on prolonged cytopenia post CAR-T infusion.

CANCERS (2022)

添加到收藏夹

Article Hematology

Preferential expansion of CD8+CD19-CAR T cells postinfusion and the role of disease burden on outcome in pediatric B-ALL

Aimee C. Talleur et al.

Summary: CD19-specific CAR T cells have potent antileukemia activity in pediatric and adult B-ALL patients, but not all patients achieve a complete response. This clinical study evaluated a new CD19-CAR T cell product in pediatric patients and showed that the treatment was safe and effective, with disease burden before infusion affecting the treatment outcome.

BLOOD ADVANCES (2022)

添加到收藏夹

Review Medical Laboratory Technology

MonitoringCAR-Tcell kinetics in clinical trials by multiparameteric flow cytometry: Benefits and challenges

Ghanashyam Sarikonda et al.

Summary: This article discusses three main areas for monitoring CAR-T therapies in clinical trials, including the development of MFC assays, operational challenges, and the relationship between cellular kinetics observed by MFC and qPCR analyses and treatment efficacy.

CYTOMETRY PART B-CLINICAL CYTOMETRY (2021)

添加到收藏夹

Article Hematology

Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies

Jordan Gauthier et al.

Summary: CD19 CAR T-cell therapy has shown significant efficacy for R/R B-cell malignancies, but durable responses are limited. Second infusions of CD19 CAR T cells (CART2) can improve outcomes, with positive therapeutic effects observed in CLL, NHL, and ALL patients after CART2.

BLOOD (2021)

添加到收藏夹

Article Hematology